The CDK/Pim/FLT3 inhibitor, ETH-155008, is currently being assessed in refractory/relapsed B-cell, NHL patients as well as CLL and SLL patients. This evidence concerns the gene FLT3 and B-cell chronic lymphocytic leukemia.